170 related articles for article (PubMed ID: 32768271)
1. Efficacy and Tolerability of Selective Internal Radiotherapy With Yttrium-90 as Consolidation Treatment After Chemotherapy in Metastatic Colorectal Cancer.
Cortesi E; Caponnetto S; Masi G; Urbano F; Mezi S; Gelibter A; Pelle G; Filippi L; Cianni R
Clin Colorectal Cancer; 2020 Dec; 19(4):e272-e276. PubMed ID: 32768271
[TBL] [Abstract][Full Text] [Related]
2. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
Gibbs P; Gebski V; Van Buskirk M; Thurston K; Cade DN; Van Hazel GA;
BMC Cancer; 2014 Dec; 14():897. PubMed ID: 25487708
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
Sofocleous CT; Garcia AR; Pandit-Taskar N; Do KG; Brody LA; Petre EN; Capanu M; Longing AP; Chou JF; Carrasquillo JA; Kemeny NE
Clin Colorectal Cancer; 2014 Mar; 13(1):27-36. PubMed ID: 24370352
[TBL] [Abstract][Full Text] [Related]
4. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Wasan HS; Gibbs P; Sharma NK; Taieb J; Heinemann V; Ricke J; Peeters M; Findlay M; Weaver A; Mills J; Wilson C; Adams R; Francis A; Moschandreas J; Virdee PS; Dutton P; Love S; Gebski V; Gray A; ; ; ; van Hazel G; Sharma RA
Lancet Oncol; 2017 Sep; 18(9):1159-1171. PubMed ID: 28781171
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
Walter T; Hawkins NS; Pollock RF; Colaone F; Shergill S; Ross PJ
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2575-2587. PubMed ID: 32715436
[TBL] [Abstract][Full Text] [Related]
6. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer.
Dutton SJ; Kenealy N; Love SB; Wasan HS; Sharma RA;
BMC Cancer; 2014 Jul; 14():497. PubMed ID: 25011439
[TBL] [Abstract][Full Text] [Related]
7. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
van Hazel GA; Heinemann V; Sharma NK; Findlay MP; Ricke J; Peeters M; Perez D; Robinson BA; Strickland AH; Ferguson T; Rodríguez J; Kröning H; Wolf I; Ganju V; Walpole E; Boucher E; Tichler T; Shacham-Shmueli E; Powell A; Eliadis P; Isaacs R; Price D; Moeslein F; Taieb J; Bower G; Gebski V; Van Buskirk M; Cade DN; Thurston K; Gibbs P
J Clin Oncol; 2016 May; 34(15):1723-31. PubMed ID: 26903575
[TBL] [Abstract][Full Text] [Related]
8. Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases.
O'Leary C; Greally M; McCaffrey J; Hughes P; Lawler LLP; O'Connell M; Geoghegan T; Farrelly C
Ir J Med Sci; 2019 Feb; 188(1):43-53. PubMed ID: 29511912
[TBL] [Abstract][Full Text] [Related]
9. Complete eradication of hepatic metastasis from colorectal cancer by Yttrium-90 SIRT.
Garrean S; Muhs A; Bui JT; Blend MJ; Owens C; Helton WS; Espat NJ
World J Gastroenterol; 2007 Jun; 13(21):3016-9. PubMed ID: 17589957
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
Gulec SA; Pennington K; Wheeler J; Barot TC; Suthar RR; Hall M; Schwartzentruber D
Am J Clin Oncol; 2013 Oct; 36(5):455-60. PubMed ID: 22643569
[TBL] [Abstract][Full Text] [Related]
12. Noncirrhotic portal hypertension: An under-reported late adverse event of SIRT in metastatic colorectal cancer patients.
Gutierrez L; Méndez S; Mitjavila M; Llop E; Salas C; Ruiz-Casado A
J Cancer Res Ther; 2019; 15(1):42-47. PubMed ID: 30880753
[TBL] [Abstract][Full Text] [Related]
13. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
14. Selective internal radiation therapy for liver metastases from colorectal cancer.
Townsend AR; Chong LC; Karapetis C; Price TJ
Cancer Treat Rev; 2016 Nov; 50():148-154. PubMed ID: 27690234
[TBL] [Abstract][Full Text] [Related]
15. Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
Wolstenholme J; Fusco F; Gray AM; Moschandreas J; Virdee PS; Love S; Van Hazel G; Gibbs P; Wasan HS; Sharma RA
Int J Cancer; 2020 Aug; 147(4):1078-1085. PubMed ID: 31840815
[TBL] [Abstract][Full Text] [Related]
16. The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres.
Pardo F; Sangro B; Lee RC; Manas D; Jeyarajah R; Donckier V; Maleux G; Pinna AD; Bester L; Morris DL; Iannitti D; Chow PK; Stubbs R; Gow PJ; Masi G; Fisher KT; Lau WY; Kouladouros K; Katsanos G; Ercolani G; Rotellar F; Bilbao JI; Schoen M
Ann Surg Oncol; 2017 Sep; 24(9):2465-2473. PubMed ID: 28653161
[TBL] [Abstract][Full Text] [Related]
17. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
Pollock RF; Colaone F; Guardiola L; Shergill S; Brennan VK
J Med Econ; 2020 Jun; 23(6):593-602. PubMed ID: 32067534
[No Abstract] [Full Text] [Related]
18. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases.
Stubbs RS; Cannan RJ; Mitchell AW
J Gastrointest Surg; 2001; 5(3):294-302. PubMed ID: 11360053
[TBL] [Abstract][Full Text] [Related]
19. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
20. Patterns of failure in colorectal patients with liver metastases after yttrium-90 radioembolization.
Schonewolf CA; Patel B; Gensure RH; Narra V; Haffty BG; Nosher JL; Jabbour SK
Am J Clin Oncol; 2014 Jun; 37(3):234-40. PubMed ID: 23275270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
